Premium
FDA Regulation of Dietary Supplements and Requirements Regarding Adverse Event Reporting
Author(s) -
Frankos V H,
Street D A,
O'Neill R K
Publication year - 2010
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2009.263
Subject(s) - food and drug administration , dietary supplement , education act , medicine , clinical pharmacology , drug labeling , adverse effect , drug , business , pharmacology , law , food science , special education , chemistry , political science
In 1994, the Dietary Supplement Health and Education Act (DSHEA) amended the Federal Food, Drug, and Cosmetic Act (FDC Act) to set up a distinct regulatory framework for what we now call dietary supplements. The DSHEA was passed with the intent of striking a balance between providing consumers access to safe dietary supplements to help maintain or improve their health and giving the US Food and Drug Administration (FDA) authority to regulate and take action against manufacturers of supplements or supplement ingredients that present safety problems, are presented with false or misleading claims, or are adulterated or misbranded. This article will present FDA's recent experience in collecting and evaluating dietary supplement adverse event data for the purpose of assuring the public that the dietary supplements they purchase are safe. Clinical Pharmacology & Therapeutics (2010) 87 2, 239–244. doi: 10.1038/clpt.2009.263